
Investment Partner
PhD in Biochemistry
Myoung-Ok Kwon
Myoung has 17 years of experience in healthcare investment and pharma research. Prior to joining Swisscom Ventures in June 2021, she managed a biotech venture fund and two public equity funds focusing on small- and mid-cap biotech companies in the field of therapeutics, diagnostics and medical device. Previously, she worked at Novartis and was responsible for research strategy & planning and portfolio review.
Deals of Myoung-Ok Kwon
Newsroom
Kyan Health raises $16.7M to upgrade workplace wellness
Kyan Health is an AI-powered enterprise solution that connects employee well-being with measurable business impact.
Nanolive SA Announces Initial Closing of Series C-1 Round
Nanolive successfully completed the initial closing of US$20 million in the Series C-1 equity financing round of investment.
Neo Medical closes Swisscom Ventures-lead USD $20.6M financing round
Proceeds to accelerate the commercial deployment of Neo Medical AI-driven ADVISEā¢ augmented reality platform for spinal surgery
Join us on January 20th for the Swisscom Ventures Romandie Community event.
Medimaps raises $20M for AI bone health software
The $20 million financing round was supported by a Swiss VC syndicate including Swisscom Ventures.